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Abstract 
Increased expression of the FXYD3 family of proteins has been associated with lung, colorectal, bladder and pancre-
atic cancers, and recent evidence suggests that elevated FXYD3 may promote tumor cell proliferation in breast cancer 
as well. However, factors involved in up-regulating the expression of FXYD3 in breast cancer have not been identified. 
We evaluated whether estrogen and the selective estrogen receptor modulator tamoxifen could regulate the expres-
sion of FXYD3 on breast cancer cells. Estrogen receptor (ER) α-positive MCF-7 and ER α-negative MDA-MB-231 human 
breast cancer cells used in our studies were treated with estrogen, tamoxifen or the combination of these agents. 
Relative expression of FXYD3 was assessed using fluorochrome-tagged antibodies and a fluorescence cytometer. 
We found that estrogen and tamoxifen, used alone or in combination, significantly increased FXYD3 on MCF-7 cells. 
FXYD3 levels did not increase compared to the control samples when ER α-negative 231 cells were treated with 
estrogen or tamoxifen, alone or in combination, indicating that ER α was required for the increased FXYD3 response. 
We showed that ER α associates with the transcription factor ZEB1 in MCF-7 cells, and that decreasing ZEB1 protein 
expression using siRNA disrupts the ability of estrogen, but not tamoxifen, to increase FXYD3 in MCF-7 cells. Our 
results indicate that there may be two mechanisms, both involving ER α and one requiring ZEB1, through which 
FXYD3 may be increased by estrogen and tamoxifen in breast cancer cells. Ongoing research endeavors are focusing 
on identifying cellular components through which estrogen and tamoxifen, alone or in combination, differentially 
regulate FXYD3 expression in human breast cancer cells.
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Background
Breast cancer is the second most common cancer among 
American women, affecting about 1 in 8 women in the 
United States during their lifetime (Siegel et  al. 2014; 
American Cancer Society 2014). It was projected that 
over 240,000 new cases of breast cancer would be diag-
nosed in women in 2014. Breast cancer is the second 
leading cause of cancer related death in women (Siegel 
et al. 2014; American Cancer Society 2014). The disease 
state is defined as a malignant tumor that typically starts 
in the stroma tissue surrounding the mammary ducts and 
metastasizes to other areas of the body. With this, the 
cells lose control of communication, repair, and differen-
tiation processes that are periodically activated in nor-
mal mammary cells. In particular, a loss of control in the 
expression and/or function of cell surface proteins can 
lead to issues with signaling and transport mechanisms 
that have a high incidence in cancer cells (Shou et  al. 
2004; Frasor 2003; Wu et al. 2011).
FXYD3 is a member of the FXYD protein family 
(Crambert et al. 2005). There are over 10 members of the 
FXYD family that have been identified and character-
ized in mammals, but FXYD3 is unique from the rest in 
that it possesses two transmembrane domains and main-
tains an uncleaved signal sequence within the protein 
(Yamamoto et  al. 2009). FXYD3 has been shown to be 
located at the cell surface and in intracellular membrane 
 compartments. FXYD3 isoforms modify the function of 
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Na+/K+-ATPase, which is further supported by the dis-
covery that parts of the FXYD3 signal overlaps with the 
α subunit of the Na+/K+-ATPase (Yamamoto et al. 2009). 
FXYD3 protein is expressed in a number of cells in nor-
mal, untransformed tissues, including the bladder, lung, 
stomach and skin, but has been reported to be highly 
overexpressed in many tumors such as breast, andro-
gen-dependent prostate, pancreatic, and colon cancer 
(Yamamoto et al. 2009; Li et al. 2014). Overexpression of 
FXYD3 is also believed to be involved in the tumorigen-
esis and development of esophageal squamous cell carci-
noma (Zhu et al. 2013). Although increased expression of 
FXYD3 is associated with various cancers, the relevant 
biological factors and their associated mechanisms of 
actions through which FXYD3 is increased in transform-
ing and cancer cell systems have not been identified.
Several hormonal factors, including estrogen, have 
been implicated in promoting the development, growth 
or spread of breast cancer tumor cells (Speirs et al. 1999; 
Ali and Coombes 2002). Elevated levels of estrogen have 
been shown to promote uncontrolled cell growth through 
the disruption of cell signaling processes, and increased 
levels of this hormone are often associated with higher 
incidences of breast cancer (Kim et al. 2013). Numerous 
studies have demonstrated that the selective estrogen 
receptor modulator (SERM) tamoxifen reduces tumor 
recurrence and lowers the chance of contralateral breast 
cancer when used in combination with chemotherapy 
(Fisher and Costantino 1999; Jordan and O’Malley 2007). 
While tamoxifen is often viewed as antagonistic to 
estrogen action when used as a treatment for hormone-
responsive breast cancer, the observation that tamoxifen 
can act as a partial estrogen agonist on gene expression 
and that women can also develop tamoxifen-resistant or 
tamoxifen-promoted tumors suggests that there may be 
one or more common pathways through which estrogen 
and tamoxifen potentially promote cancer development 
(Fisher and Costantino 1999; Jordan and O’Malley 2007). 
With this in mind, we examined whether exposure of 
cells to estrogen, alone or in combination with tamoxifen, 
could regulate FXYD3 expression in human breast cancer 
cells. We also set out to determine if regulation of FXYD3 
expression by estrogen and/or tamoxifen was associated 
with the presence and action of the estrogen receptor 
(ER) α protein and the transcription factor ZEB1.
Methods
Cells and cell lines
Human mammary carcinoma cell lines MCF-7 and 
MDA-MB-231 (231 cells) were purchased from ATCC. 
MCF-7 cells were maintained on MEM. MDA-MB-231 
cells were maintained on Leibowitz L-15 media. All 
media used for the maintenance of cancer cells were 
supplemented with 10% fetal bovine serum (FBS) and 
antibiotic/antimycotic solution (penicillin G, strepto-
mycin, and amphotericin B). All cell lines were main-
tained in incubators at 37°C and 5% CO2 under hydrating 
conditions.
Reagents
Cell culture reagents, including FBS, antibiotic/antimy-
cotic solution, Trypsin-EDTA solution, MEM, Leibovitz 
L-15 media and Opti-MEM were GIBCO products pur-
chased from Invitrogen/Life Technologies (Grand Island, 
NY, USA). Chemicals used in buffer preparations and the 
following specific reagents were purchased from Sigma 
Chemical Company (St. Louis, MO, USA): 17β-estradiol 
(estrogen; E2), tamoxifen (4-hydroxy-tamoxifen; Tam). 
Anti-human FXYD3, anti-human E-cadherin, anti-
human ZEB1, and anti-human ER α primary and sec-
ondary antibodies and molecular weight markers for 
SDS-PAGE, and ZEB1 siRNa and siRNA transfection 
reagent were all purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA).
Flow cytometry staining and analysis of FXYD3 
and E‑cadherin surface expression
For experiments evaluating FXYD3 and E-cadherin sur-
face expression, MCF-7 or 231 cells were treated with 
control vehicle [phosphate buffered saline, (PBS), or 
PBS containing 0.1% ethanol] or with the following rea-
gents, alone or in combination, for 48 h: 1 nM 17-beta-
estradiol (E2), 10  nM Tamoxifen (Tam). Treated cells 
were removed from flasks by trypsin-EDTA, pelleted 
by centrifugation (600×g, 5  min), and resuspended in 
residual media. Blocking antibody (5  μl of unlabeled, 
normal hamster IgG) was added to each tube and put on 
ice for 15 min. Tubes were gently vortexed every 5 min. 
Following the blocking step, each tube containing the 
entire treated cell population was split evenly by volume 
into three tubes, referred to as groups 1–3. Group 1 cells 
received the hamster blocking antibody only, group 2 
cells received isotype antibody, and group 3 received spe-
cific anti-human FXYD3 or anti-human E-cadherin pri-
mary antibody. The specific primary antibody (FXYD3 or 
E-cadherin) was added to group 3 tubes and set on ice 
for 15  min, with vortexing every 5  min. Phycoerythrin 
(PE)-labeled secondary antibody was added to both tubes 
2 and 3 and the tubes were set on ice for 15  min. Cold 
PBS (3 ml) was added to all tubes and cells were pelleted 
at 600×g for 5 min. PBS was decanted from all tubes and 
500 µl of PBS was added to the cell pellet in each tube. 
Cells were resuspended and the samples were transferred 
to microcentrifuge tubes and analyzed for FXYD3 or 
E-cadherin expression using a Guava PC flow cytometer 
and Guava Express software.
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Immunoprecipitation
MCF-7 cells were treated with various reagents for 24 or 
48 h, and then harvested. Cell pellets were resuspended 
in NP-40 lysis solution (1% NP-40 in PBS) and vortexed, 
to form cell lysates. Lysates were maintained on ice. 
Protein content of cell lysate samples were determined 
through the use of a Pierce BCA Protein Assay Kit with 
a bovine serum albumin (BSA) standard curve (Pierce 
Chemical Co., Rockford, IL, USA). For immunoprecipita-
tion of ZEB1 proteins, aliquots of cell lysates were placed 
into microcentrifuge tubes on an equivalent total protein 
basis in order to equalize the amount of protein in the 
samples that were to be immunoprecipitated. Adjusted 
volumes (so that each tube contains the same amount of 
total protein) were added to microcentrifuge tubes from 
each lysate and 300  μl of 20  mM tris-buffered saline 
(TBS, pH 7.5) was added to each tube. Anti-human ZEB1 
primary antibody (10 μl; 2 μg) was added to each sam-
ple and allowed to mix on a rotator, end-over-end, in a 
4°C cold room for 1 h. Protein G-Sepharose beads were 
resuspended in TBS and 100 μl of bead slurry was added 
to each tube and tubes allowed to mix for an additional 
1 h on a rotator in the cold room. The samples were then 
centrifuged (600×g, 5  min, 4°C) to pellet the beads and 
the supernatant was discarded. The bead pellet in each 
tube was washed with 100 μl of 1% NP-40 lysis buffer and 
200 μl of 20 mM TBS buffer and mixed on a rotator in the 
cold room for 10  min. These samples were centrifuged 
and the supernatant was discarded. Two more wash 
steps were carried out using 300 μl of 20 mM TBS and 
the bead pellets were kept each time. After the final wash, 
20  μl of loading buffer containing β-mercaptoethanol 
(BME) was added to each sample. Just prior to loading 
SDS-PAGE gels, samples were centrifuged briefly at high 
speed to pellet the Sepharose beads.
Protein analysis by SDS‑PAGE and western 
immunoblotting for estrogen receptor
Following immunoprecipitation of ZEB1 proteins and 
removal of the protein-G beads, immunoprecipitated 
samples were boiled for 3  min and then loaded onto 
10% polyacrylamide gels. Proteins were separated 
according to molecular weight by SDS-PAGE under 
reducing conditions and transferred to PVDF mem-
branes by iBlot turboblotter. Membranes were subse-
quently immunoblotted with rabbit anti-human ER 
α primary antibodies at a concentration of 1:200 in a 
5% blocking solution (5% carnation non-fat dry milk 
in 20  mM TBS, pH 7.5). Secondary antibodies (goat 
anti-rabbit horseradish peroxidase linked) were used 
at a concentration of 1:2000 in the same 5% blocking 
solution. Membranes were washed three times in TBST 
(TBS containing 0.1% tween 20). Washed membranes 
were then exposed to BIO-RAD Clarity luminol-con-
taining reagents and imaging was carried out on a 
digital Versadoc imager. The digital images were then 
examined for banding patterns for proteins and corre-
sponding molecular weight markers using Multi-ana-
lyst software.
Transfection of breast cancer cells with ZEB1 siRNA
We were interested in assessing the potential role of the 
ZEB1 protein in mediating the regulation of FXYD3 
expression by estrogen and tamoxifen. Towards that goal, 
we transfected cells with siRNA directed against human 
ZEB1 in order to decrease ZEB1 expression. MCF-7 cells 
were grown in 6-well plates until 50% confluency. Main-
tenance media was replaced with antibiotic free Opti-
MEM for 24 h prior to transfection. Transfection of the 
cells was carried out using Santa Cruz Transfection Rea-
gents. Working under a sterile tissue culture hood, Opti-
MEM was exchanged for 1  ml of serum-free, antibiotic 
free Opti-MEM for each well and plates were placed in 
the incubator while siRNA-lipid complexes were pre-
pared. For each well to be transfected, two microcentri-
fuge tubes, one for diluting the siRNA (Solution A) and 
one for diluting the lipid transfection reagent (Solution 
B) were prepared. Solution A tubes contained 100  μl 
of Opti-MEM and 6 μl of the ZEB1 siRNA. Solution B 
tubes contained 100 μl of Opti-MEM and 6 μl of trans-
fection reagent. For each pair of tubes, the A and B tubes 
were combined by transferring Solution A slowly drop-
wise into Solution B. The combined contents now in tube 
B were gently mixed up and down with a micropipette to 
insure a uniform reaction of the reagents. The combined 
solution was incubated at room temperature (RT) for 
25 min.
After the incubation period, 800 μl of Opti-MEM was 
added to the combined A and B tube and gently mixed 
with a pipette. At this point the plates were removed from 
the incubator and the antibiotic free media was removed 
from the transfection wells. The entire 1  ml combined 
volume containing the transfection siRNA-lipid com-
plexes were added to the respective wells in a drop-wise 
fashion to overlay the cells. The cells were incubated 
overnight for 24  h and then the media was changed to 
1  ml of media containing serum and antibiotics. Trans-
fected cells were treated with PBS/ethanol vehicle, estro-
gen, tamoxifen, or the combination of estrogen and 
tamoxifen for 24 h. Flow cytometry was used to analyze 
FXYD3 levels of treated transfected cells, as described. 
For comparison controls for various experiments, some 
wells of cells were left untransfected, some were mock 
transfected where they were exposed to all transfection 
reagents but not siRNA, and some were transfected with 
non-targeting siRNA.
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Statistical analyses
FXYD3 expression data were statistically analyzed by 
ANOVA using Microsoft Excel Software. Significant dif-
ference between pairs of treatment groups was deter-
mined by paired Student’s t tests. Differences between 
treatment groups at a level of p < 0.05 was considered to 
be statistically significant.
Results
Estrogen and tamoxifen exposure increases cell surface 
expression of FXYD3
We set out to evaluate whether estrogen and tamox-
ifen could affect the expression of FXYD3 or E-cadherin 
on the surface of MCF-7 and 231 breast cancer cells. 
MCF-7 or 231 cells maintained in culture were treated 
with PBS/0.1% ethanol vehicle alone (PBS), or with 
1 nM estrogen or 10 nM tamoxifen alone, or with these 
reagents in combination, for 48  h. Cells were harvested 
and FXYD3 expression was determined by flow cytom-
etry, as described in the “Methods”. All treatment agents 
significantly increased cell surface expression of FXYD3 
in MCF-7 cells when compared to PBS/ethanol con-
trol (Figure  1). In contrast to results obtained with ER-
positive MCF-7 cells, exposure of ER-negative 231 cells 
to estrogen, tamoxifen or the combined treatment failed 
to evoke increases in FXYD3 expression, resulting in 
FXYD3 levels at or below those of control cells (Figure 2). 
Treated MCF-7 cells were also evaluated for altered 
expression of E-cadherin. In contrast to results obtained 
for FXYD3 expression, exposure of MCF-7 cells to 1 nM 
estrogen, 10 nM tamoxifen or the combination of agents 
for 48 h failed to evoke changes in cell surface expression 
of E-cadherin when compared to control, vehicle-treated 
cells (data not shown).
ZEB1 associates with ER in MCF‑7 cells
We were interested in determining whether the tran-
scription factor ZEB1 associated with ER α in the pres-
ence or absence of estrogen or tamoxifen in MCF-7 cells. 
MCF-7 cells maintained in culture were treated with 
PBS/ethanol vehicle (control), 1  nM estrogen, 10  nM 
tamoxifen or with estrogen in combination with tamox-
ifen for 48  h. ZEB1 proteins were immunoprecipitated 
from cell lysates in non-reducing conditions using anti-
human ZEB1 antibodies, as described in the “Methods”. 
Proteins from immunoprecipitated samples were sepa-
rated according to molecular weight by SDS-PAGE and 
transferred to PVDF membranes. Membranes were then 
probed with anti-ER α primary and HRP-labeled second-
ary antibodies and subjected to image analysis for band-
ing patterns. Our results indicate that the ZEB1 protein 
associates with ER in control treated cells, as evidenced 
by the presence of ER α in the ZEB1-immunoprecip-
itated control cell lysate (Figure 3, lane 2). This associa-
tion between ZEB1 and ER was maintained, and in some 
instances appeared to increase, as evidenced by the 
darker ER bands, for cells treated with estrogen, tamox-
ifen or the combination of treatments (Figure 3).
ZEB1 protein is required for up‑regulation of FXYD3 
expression by estrogen
With the observations that estrogen exposure increased 
expression of FXYD3 in MCF-7 breast cancer cells, 
and that exposure of these cells to estrogen increased 
Figure 1 FXYD3 levels in MCF-7 cells. MCF-7 cells were treated for 48 h with PBS/0.1% ethanol control vehicle, 1 nM estrogen, 10 nM tamoxifen 
or with estrogen in combination with tamoxifen, and expression of FXYD3 was determined by flow cytometry using anti-FXYD3 antibodies and 
a Guava PC flow cytometer, as described in the “Methods”. Each bar represents the mean ± SD of FXYD3 fluorescence per cell for six samples 
obtained in separate experiments. Asterisk significant difference (p < 0.05) from PBS/ethanol-treated control cells.
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the association of ER with the ZEB1 protein, we set out 
to determine whether declines in ZEB1 levels would 
alter the ability of estrogen or tamoxifen to regulate 
FXYD3 expression. MCF-7 cells maintained in culture 
were either left untransfected, were mock transfected 
with non-targeting reagents, or were transfected with 
human ZEB1 siRNA in order to decrease ZEB1 levels, as 
described in the “Methods”. Following the transfection 
procedure and treatment of cells with PBS/ethanol con-
trol vehicle, 1 nM estrogen, 10 nM tamoxifen or the com-
bined treatment of estrogen and tamoxifen for 36 h, cells 
were harvested and FXYD3 expression was determined 
by flow cytometry. As with our initial experimental 
results, exposure of untransfected or mock transfected 
MCF-7 cells (data combined) to estrogen, tamoxifen or 
the combination of estrogen and tamoxifen increased 
expression of FXYD3 when compared to the PBS/etha-
nol control (Figure  4). Of particular interest, however, 
is that upon transfection with ZEB1 siRNA, expression 
levels of FXYD3 in PBS/ethanol vehicle-treated control 
cells increased substantially (Figure  4). Moreover, expo-
sure of these ZEB1 siRNA transfected cells to estrogen or 
estrogen in combination with tamoxifen promoted a sub-
stantial decline, rather than increase, in FXYD3 expres-
sion (Figure 4). In contrast to the estrogen exposed cells, 
exposure of ZEB1 siRNA transfected cells to tamoxifen 
alone did not result in substantial increases or decreases 
in FXYD3, but with cells maintaining levels of FXYD3 at 
or slightly above those elevated levels detected for vehi-
cle-treated ZEB1 siRNA transfected cells (Figure 4).
Discussion
The FXYD genes encode for proteins that function to 
regulate the transport functions of Na+/K+ ATPases 
Figure 2 FXYD3 levels in MDA-MB-231 cells. MDA-MB-231 cells were treated for 48 h with PBS/0.1% ethanol control vehicle, 1 nM estrogen, 
10 nM tamoxifen or with estrogen in combination with tamoxifen, and expression of FXYD3 was determined by flow cytometry using anti-FXYD3 



















Figure 3 ZEB1 associates with estrogen receptor in MCF-7 cells. 
MCF-7 cells were treated with PBS/0.1% ethanol control vehicle, 1 nM 
estrogen, 10 nM tamoxifen or with estrogen in combination with 
tamoxifen for 24 h. ZEB1 was immunoprecipitated from cell lysates 
using anti-ZEB1 antibodies, as described in “Methods”. Immuno-
precipitated proteins were separated by SDS-PAGE and transferred 
to PVDF membranes. Presence of ER α in immunoprecipitated 
samples was determined by Western immunoblotting using anti-ER 
α antibodies, as described in “Methods”. Imaging of membranes was 
performed with a Versadoc imager and Multi-analyst software.
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in a variety of normal cell systems (Crambert et  al. 
2005; Yamamoto et  al. 2009). One member of this fam-
ily, FXYD3, not only serves to regulate ATPase func-
tion in normal physiological systems, but several studies 
have shown that overexpression of this member of the 
FXYD family is associated with a number of cancers, 
and has been implicated in direct action in the forma-
tion of at least one type of cancer (Yamamoto et  al. 
2009; Li et al. 2014; Zhu et al. 2013; Grzmil et al. 2004). 
While increased expression of FXYD3 has been associ-
ated with breast cancer, the factors that promote up-reg-
ulation of this protein in mammary cells have not been 
identified. We report in the results of our current study 
that both estrogen and the SERM tamoxifen can signifi-
cantly increase the expression of FXYD3 in ER α-positive, 
MCF-7 human breast cancer cells. Moreover, the high-
est levels of FXYD3 were detected in cells exposed to 
both estrogen and tamoxifen. To our knowledge, this is 
the first report showing that FXYD3 can be increased by 
estrogen and tamoxifen in breast cancer cells. Our obser-
vation that up-regulation of FXYD3 by either factor was 
not observed in ER α-negative 231 cells suggests that the 
effect of estrogen and tamoxifen on the expression of 
FXYD3 requires the presence of the α isoform of the ER 
protein.
Our observation that estrogen and tamoxifen could 
serve to increase FXYD3 expression in breast cancer 
cells prompted us to examine potential mechanisms 
through which this increased gene expression might 
be occurring. Recent reports had shown that the tran-
scriptional repressor ZEB1 mediated the down-reg-
ulation of FXYD3 in human mammary cells that had 
been exposed to transforming growth factor beta (TGF 
beta) (Yamamoto et  al. 2011). The authors went on to 
show that the silencing of ZEB1 expression prompted 
an increase in FXYD3 in cells that had been suppressed 
by TGF beta (Yamamoto et  al. 2011). Since estrogen 
has been known to regulate gene expression through 
alteration of gene transcription (Kim et al. 2013; Jordan 
and O’Malley 2007), we set out to determine whether 
the increases we observed in FXYD3 for cells exposed 
to estrogen or tamoxifen could be associated with the 
action of ZEB1. We initially sought to see if the ER 
protein and ZEB1 proteins actually interacted in our 
MCF-7 cells. Results of immunoprecipitation experi-
ments showed that ER α and ZEB1 associated with one 
another in PBS-treated cells, and that this interaction 
was maintained or increased in the presence of estro-
gen, tamoxifen or the combination of these agents. We 
then sought to determine if there was a central role 
for ZEB1 in the up-regulation of FXYD3 by decreas-
ing the ZEB1 protein and seeing if the base levels and 
hormone-influenced levels of FXYD3 were changed as 
a result. Using siRNA directed against human ZEB1, 
we lowered the amount of ZEB1 in transfected MCF-7 
cells and then assessed cells for basal levels of FXYD3 
and evaluated whether suppression of ZEB1 altered cel-
lular responses to estrogen and tamoxifen. We found 
that the mere suppression of ZEB1 protein levels in 
MCF-7 cells served to promote an increase in FXYD3 
protein levels. Treatment of these cells with estrogen 
or estrogen in combination with tamoxifen failed to 
increase FXYD3 and, in fact, tended to evoke decreases 
in FXYD3 to levels below those of the control cell pop-
ulation. In contrast, treatment of cells transfected with 
ZEB1 siRNA with tamoxifen alone, in the absence of 
additional estrogen, maintained elevated FXYD3 levels 
consistent with or slightly above those of the control 
PBS treated transfected cells.
Our observations provide the first evidence of a mech-
anism through which estrogen can serve to up-regulate 
FXYD3 in human breast cancer cells. The ability of estro-
gen to increase FXYD3 expression appears to require 
both the presence of ER α and ZEB1 in the MCF-7 cell 
system. It is of interest that the suppression of ZEB1 pro-
teins in MCF-7 cells suppresses the ability of estrogen 
to increase FXYD3, suggesting that the presence of the 
ZEB1 protein is integral to the action of ER α in enhanc-
ing expression of FXYD3. Estrogen, working through ER 


































Figure 4 Effect of decreased ZEB1 expression on FXYD3 expression. 
Decreasing ZEB1 expression was achieved by transfecting MCF-7 cells 
with siRNA targeting human ZEB1. Following the transfection pro-
cedure, cells were treated with control PBS/ethanol vehicle, or with 
estrogen, tamoxifen or with estrogen in combination with tamoxifen 
for 24 h. Expression of FXYD3 on cells was determined by flow cytom-
etry using a Guava PC instrument and Guava Express software. Each 
bar represents the mean ± SD of FXYD3 fluorescence per cell for six 
to eight samples obtained in separate experiments. FXYD3 expression 
data from untransfected or mock transfected (non-targeting siRNA) 
cells were pooled together. Asterisk significant difference from ZEB1 
siRNA transfected, control-treated cells.
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in MCF-7 cells, suggesting that increased ZEB1 levels are 
related to the pro-cancer phenotype promoted by estro-
gen action within these cells (Guo et al. 2012). Whether 
the action of estrogen to increase FXYD3 expression, 
mediated by ER α, involves direct activation or inacti-
vation of ZEB1, and/or involvement of other transcrip-
tional regulators has yet to be determined. Other groups 
have shown that activation of ZEB1 results in the active 
repression of the expression of other genes, including 
those that are involved in cell polarity differentiation of 
epithelial cells and those that are involved in EMT in 
cancer development (Spaderna et  al. 2008; Aigner et  al. 
2007). In addition, a separate report indicates that ER α 
and ZEB1 work in opposition to one another in control-
ling the expression of microRNAs in breast cancer cells 
(Simonini et  al. 2010). Our observation that decreasing 
ZEB1 results in increased levels of FXYD3 expressed 
in control, vehicle-treated cells could be indicative of a 
block to, or reversing of, repression of gene expression 
by ZEB1, consistent with results of previously published 
studies (Yamamoto et al. 2011). Of particular interest in 
our own findings, however, is that the decline in ZEB1 
appears either to prevent up-regulation of FXYD3 by 
estrogen and/or alters the action of the estrogen–ER 
α interaction to act as a suppressor of FXYD3 expres-
sion, while simultaneously permitting tamoxifen to pro-
mote or maintain elevated FXYD3 protein levels in this 
cell system. This indicates that the SERM tamoxifen acts 
more like an estrogen agonist rather than antagonist on 
FXYD3 expression in either the presence or absence of 
ZEB1. This is in contrast to results of another study that 
suggests that the presence of ZEB1, and not the absence 
of ZEB1, is associated with tamoxifen resistance in breast 
cancer cells (Guo et  al. 2012). There is some evidence 
in uterine cell systems that ZEB1 may be positioned on 
chromatin in target genes in at least three conformations 
(repressive, poised, active), and perhaps this potential for 
at least three conformations of ZEB1 might be relevant 
to the differences we see in how regulation of ZEB1 pro-
tein level affects the ability of estrogen and tamoxifen to 
regulate FXYD3 (Spoelstra et al. 2006). In fact, our obser-
vation that tamoxifen can promote or maintain elevated 
levels of FXYD3 in the absence or diminished levels of 
ZEB1, contrary to the results obtained with estrogen 
exposure, might give some insight into a potential avenue 
through which tamoxifen might contribute to cancer 
progression, rather than suppression, in ER α-positive 
breast cancers. Ongoing research efforts are focusing 
on determining what specific transcriptional factors are 
involved in the regulation of FXYD3 expression in breast 
cancer cells by estrogen, tamoxifen, and the combination 
of these agents.
Conclusions
Our study provides the first primary evidence of estro-
gen and the SERM tamoxifen serving as up-regulators 
of FXYD3 on human breast cancer cells. Our study also 
suggests that the mechanisms through which estro-
gen and tamoxifen upregulate FXYD3 differ from one 
another, with both agents appearing to require the pres-
ence of ER α, but with estrogen action also requiring 
the presence of ZEB1. Our future studies will focus on 
the mechanisms through which these factors influence 
expression of FXYD3 on human breast cancer cells, and 
analysis of how such changes in FXYD3 evoked by estro-
gen or tamoxifen affect proliferative activity of these cells.
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